ArticleFrontiers in medicine2025
Clinical impact of early microchimerism dynamics after transplantation with enhanced dual-conditioning regimen in hematological diseases.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Microchimerism dynamics following allogeneic hematopoietic stem cell transplantation (allo-HSCT) may predict engraftment and clinical outcomes. This study aimed to quantify microchimerism changes and assess their clinical significance. Methods: In this retrospective study, eighteen patients undergoing allo-HSCT received either an enhanced dual-conditioning (EDCT) regimen (fludarabine/busulfan/cytarabine plus cyclophosphamide 200 mg/kg) or a modified EDCT regimen. Microchimerism levels were serially monitored from day +1 post-transplantation. Results: Complete donor chimerism (CDC) was achieved in 16/18 patients (88.9%) at a median time of 14 days (range, 9-24). The median neutrophil and platelet engraftment times were 15 days (range, 11-28) and 25 days (range, 10-80 in 16 patients who had platelet engraftment), respectively. Among them, eight patients retained constant CDC, 3 developed one increasing mixed chimerism (IMC), while 5 had multiple IMCs. Patients with constant CDC demonstrated faster platelet engraftment (median, 19.5 vs. 40 days, Conclusion: Early microchimerism dynamics correlate with engraftment efficiency and survival outcomes in allo-HSCT patients, suggesting its clinical utility for timely intervention and personalized treatment adjustment. The promising long-term outcomes support the applicability of this regimen and monitoring approach across transplantation modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.